According to GlobalData’s medical device pipeline database, 14 Hemoglobin Point of Care (POC) Tests devices are in various stages of development globally. GlobalData’s report Hemoglobin Point of Care (POC) Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, eight are in active development, while the remaining six are in an inactive stage of development. There are four products in the early stages of development, and the remaining four are in the late stages of development.

A Hemoglobin POC test is ordered to evaluate the hemoglobin content of blood as part of a general health checkup; to screen for and help diagnose conditions that affect red blood cells (RBCs); such as anaemia (low hemoglobin) or polycythemia (high hemoglobin), to assess the severity of these conditions and to monitor response to treatment. One Hb cartridge/microcuvette refers to one test.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Hemoglobin Point of Care (POC) Tests pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Hemoglobin Point of Care (POC) Tests devices. Overall, most of these Hemoglobin Point of Care (POC) Tests pipeline devices are being developed by private entities.

Key players involved in the active development of Hemoglobin Point of Care (POC) Tests include BioMedomics, Biosurfit, DxDiscovery, Hemex Health, MiCo BioMed, Retham Technologies, Sanguina, T2 Biosystems, University of Florida and VitaMe Technologies.

For a complete picture of the developmental pipeline for Hemoglobin Point of Care (POC) Tests devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.